-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 HJrdSeKIpMb8BCDVoZ/j8KIy0c9k9cCz7CPtn5uk3niAMcYpHD4bXU8Nq5nBMMyj
 WdylllpY71eDBhnIQ+X+HQ==

<SEC-DOCUMENT>0001144204-04-023004.txt : 20041229
<SEC-HEADER>0001144204-04-023004.hdr.sgml : 20041229
<ACCEPTANCE-DATETIME>20041229125638
ACCESSION NUMBER:		0001144204-04-023004
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20041228
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
FILED AS OF DATE:		20041229
DATE AS OF CHANGE:		20041229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRAINSTORM CELL THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001137883
		STANDARD INDUSTRIAL CLASSIFICATION:	TELEGRAPH & OTHER MESSAGE COMMUNICATIONS [4822]
		IRS NUMBER:				912061050
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-61610
		FILM NUMBER:		041230335

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 103-158TH HILLSIDE AVE.
		CITY:			VICTORIA
		STATE:			A1
		ZIP:			00000
		BUSINESS PHONE:		250-519-0553

	MAIL ADDRESS:	
		STREET 1:		SUITE 103-158TH HILLSIDE AVE.
		CITY:			VICTORIA
		STATE:			A1
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GOLDEN HAND RESOURCES INC
		DATE OF NAME CHANGE:	20030827

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WIZBANG TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010409
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v10498_8k.txt
<TEXT>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549


                                    FORM 8-K


                                 CURRENT REPORT


     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


       Date of Report (Date of earliest event reported) December 28, 2004


                        BrainStorm Cell Therapeutics Inc.
             (Exact name of registrant as specified in its charter)

          Washington                   333-61610                   912061053
 (State or other jurisdiction         (Commission               (IRS Employer
      of incorporation)               File Number)           Identification No.)

                              36 Derech Bait Lechem
                             Jerusalem, Israel 77002
               (Address of principal executive offices) (Zip Code)


      Registrant's telephone number, including area code   011-972-2-6737445

                                       N/A
         (Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

o     Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

ITEM 5.02(D)       APPOINTMENT OF NEW DIRECTORS

On December 28, 2004 our Board of Directors increased its size from two to three
directors and appointed Mr. Michael Greenfield (Ben-Ari) to serve as a director.

Since 1997, Mr. Greenfield (Ben-Ari), age 45, has served as manager of Evergreen
Field Enterprises, his own consulting company, where he specializes in
investment consulting and portfolio management. From 1991 to 1997, Mr.
Greenfield (Ben-Ari) served as Vice President of Marketing at Bank Leumi. Mr.
Greenfield holds an MBA from Tel-Aviv University and a BA from Brandeis
University.

Mr. Greenfield (Ben-Ari) is not a party to any transaction, or series of
transactions, required to be disclosed pursuant to Item 404 of Regulation S-B.


<PAGE>

                                   SIGNATURES


        Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: December 28, 2004


BRAINSTORM CELL THERAPEUTICS, INC.


/s/ Yaffa Beck
- ------------------------------
Name: Yaffa Beck
Title: President & CEO


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
